The MiRacle in Pancreatic Cancer by MiRNAs: Tiny Angels or Devils in Disease Progression

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 May 31

PMID 27240340

Citations 12

Authors

Zuhair Hawa

Inamul Haque

Arnab Ghosh

Snigdha Banerjee

LaCoiya Harris

Sushanta K Banerjee

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and high mortality. Surgical resection is the only potentially curative treatment of patients with PDAC. Because of the late presentation of the disease, about 20 percent of patients are candidates for this treatment. The average survival of resected patients is between 12 and 20 months, with a high probability of relapse. Standard chemo and radiation therapies do not offer significant improvement of the survival of these patients. Furthermore, novel treatment options aimed at targeting oncogenes or growth factors in pancreatic cancer have proved unsuccessful. Thereby, identifying new biomarkers that can detect early stages of this disease is of critical importance. Among these biomarkers, microRNAs (miRNAs) have supplied a profitable recourse and become an attractive focus of research in PDAC. MiRNAs regulate many genes involved in the development of PDAC through mRNA degradation or translation inhibition. The possibility of intervention in the molecular mechanisms of miRNAs regulation could begin a new generation of PDAC therapies. This review summarizes the reports describing miRNAs involvement in cellular processes involving pancreatic carcinogenesis and their utility in diagnosis, survival and therapeutic potential in pancreatic cancer.

Citing Articles

Circulating miRNAs as Noninvasive Biomarkers for PDAC Diagnosis and Prognosis in Mexico.

Alvarez-Hilario L, Salmeron-Barcenas E, Avila-Lopez P, Hernandez-Montes G, Arechaga-Ocampo E, Herrera-Goepfert R Int J Mol Sci. 2023; 24(20).

PMID: 37894871 PMC: 10607652. DOI: 10.3390/ijms242015193.

Pancreatic Ductal Adenocarcinoma and Nutrition: Exploring the Role of Diet and Gut Health.

Gualtieri P, Cianci R, Frank G, Pizzocaro E, De Santis G, Giannattasio S Nutrients. 2023; 15(20).

PMID: 37892540 PMC: 10610120. DOI: 10.3390/nu15204465.

Micro-RNA Analysis of Pancreatic Cyst Fluid for Diagnosing Malignant Transformation of Intraductal Papillary Mucinous Neoplasm by Comparing Intraductal Papillary Mucinous Adenoma and Carcinoma.

Shirakami Y, Iwashita T, Uemura S, Imai H, Murase K, Shimizu M J Clin Med. 2021; 10(11).

PMID: 34067335 PMC: 8196884. DOI: 10.3390/jcm10112249.

Dietary inflammatory index and pancreatic cancer risk: a systematic review and dose-response meta-analysis.

Guo Z, Hong Y, Cheng Y Public Health Nutr. 2021; 24(18):6427-6435.

PMID: 33843543 PMC: 11148588. DOI: 10.1017/S1368980021001579.

Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma.

Sagami R, Yamao K, Nakahodo J, Minami R, Tsurusaki M, Murakami K Cancers (Basel). 2021; 13(5).

PMID: 33668239 PMC: 7956417. DOI: 10.3390/cancers13050945.

References

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

Lloyd R, Erickson L, Jin L, Kulig E, Qian X, Cheville J . p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999; 154(2):313-23. PMC: 1850003. DOI: 10.1016/S0002-9440(10)65277-7. View

Ni X, Yang J, Li M . Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Lett. 2012; 324(2):179-85. PMC: 3411904. DOI: 10.1016/j.canlet.2012.05.013. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Nakata K, Ohuchida K, Mizumoto K, Kayashima T, Ikenaga N, Sakai H . MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011; 150(5):916-22. DOI: 10.1016/j.surg.2011.06.017. View

Banyard J, Chung I, Wilson A, Vetter G, Le Bechec A, Bielenberg D . Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep. 2013; 3:3151. PMC: 3818652. DOI: 10.1038/srep03151. View

Wang C, Chen C, More S, Hsiao P, Hung W, Li W . The tetraindole SK228 reverses the epithelial-to-mesenchymal transition of breast cancer cells by up-regulating members of the miR-200 family. PLoS One. 2014; 9(6):e101088. PMC: 4072721. DOI: 10.1371/journal.pone.0101088. View

Van Rooij E, Purcell A, Levin A . Developing microRNA therapeutics. Circ Res. 2012; 110(3):496-507. DOI: 10.1161/CIRCRESAHA.111.247916. View

10.

Song L, Zhang W, Chang Z, Pan Y, Zong H, Fan Q . PU.1 Is Identified as a Novel Metastasis Suppressor in Hepatocellular Carcinoma Regulating the miR-615-5p/IGF2 Axis. Asian Pac J Cancer Prev. 2015; 16(9):3667-71. DOI: 10.7314/apjcp.2015.16.9.3667. View

11.

Xu M, Gu M, Zhang K, Zhou J, Wang Z, Da J . miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. Diagn Pathol. 2015; 10:24. PMC: 4419389. DOI: 10.1186/s13000-015-0255-7. View

12.

Gironella M, Seux M, Xie M, Cano C, Tomasini R, Gommeaux J . Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104(41):16170-5. PMC: 2042180. DOI: 10.1073/pnas.0703942104. View

13.

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P . Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013; 21(5):986-94. PMC: 3666633. DOI: 10.1038/mt.2013.35. View

14.

Williams L, Veliceasa D, Vinokour E, Volpert O . miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One. 2014; 8(12):e83991. PMC: 3877136. DOI: 10.1371/journal.pone.0083991. View

15.

Lam S, Mak A, Yam J, Cheung A, Ngan H, Wong A . Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther. 2014; 22(4):743-51. PMC: 3982489. DOI: 10.1038/mt.2014.1. View

16.

Park J, Lee E, Esau C, Schmittgen T . Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009; 38(7):e190-9. DOI: 10.1097/MPA.0b013e3181ba82e1. View

17.

Wellner U, Brabletz T, Keck T . ZEB1 in Pancreatic Cancer. Cancers (Basel). 2013; 2(3):1617-28. PMC: 3837326. DOI: 10.3390/cancers2031617. View

18.

Luo G, Long J, Cui X, Xiao Z, Liu Z, Shi S . Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int J Oncol. 2013; 42(3):979-84. DOI: 10.3892/ijo.2013.1780. View

19.

Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H . Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2009; 126(1):73-80. DOI: 10.1002/ijc.24687. View

20.

Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M . miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene. 2014; 34(13):1629-40. DOI: 10.1038/onc.2014.101. View